This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Transcription Factor Therapeutics, Inc.
Drug Names(s): NF-kappaB Decoy
Description: Avrina (NF-kB Decoy) is a highly selective and potent oligodeoxynucleotide inhibitor of the transcription factor, NF-kB, which is implicated in inflammatory diseases.
Deal Structure: In June 2008, Anesiva announced that it out-licensed all worldwide rights to its NF-kappa B Decoy (NF-kB Decoy) program, which includes Avrina, to Transcription Factor Therapeutics (TFT).
Under the terms of the agreement, Anesiva will receive an upfront license fee, with additional payments dependent on development and regulatory milestones potentially totaling up to $114 million if two products are commercialized. Anesiva would also be entitled to royalty payments upon successful commercialization of any drug candidate(s). Additional terms were not disclosed. TFT will be responsible for the future development of Avrina, and intellectual property associated with the NF-kB Decoy program will be transferred to TFT.
In August 2009, Anesiva and Arcion Therapeutics announced the signing of a definitive merger agreement.
In December 2009, Anesiva announced that it was unable to satisfy the closing conditions set forth in the Agreement and Plan of Merger with Arcion Therapeutics....See full deal structure in Biomedtracker
Partners: Anesiva, Inc.
Additional information available to subscribers only: